表紙
市場調查報告書

液態切片 (液態生物檢體)的全球市場:2020年∼2028年

Global Liquid Biopsy Market Forecast 2020-2028

出版商 Inkwood Research 商品編碼 947605
出版日期 內容資訊 英文 248 Pages
商品交期: 2-3個工作天內
價格
液態切片 (液態生物檢體)的全球市場:2020年∼2028年 Global Liquid Biopsy Market Forecast 2020-2028
出版日期: 2020年07月27日內容資訊: 英文 248 Pages
簡介

全球液態切片 (液態生物檢體) 市場在2020年∼2028年的預測期間內,預計將以年複合成長率20.50%的速度成長。市場成長的促進因素,是精密醫療的成長,政府的配合措施劇增,老年人的癌症增加,液態生物檢體的可能性增加,技術的進步。

本報告提供全球液態切片 (液態生物檢體) 市場相關調查分析,市場概要,市場動態,各市場區隔的市場分析,競爭情形等相關的系統性資訊。

目錄

第1章 調查範圍和調查手法

第2章 摘要整理

第3章 市場動態

  • 市場定義
  • 主要促進因素
  • 主要阻礙因素

第4章 主要分析

  • 波特的五力分析
  • 主要的舉措
  • 法律規範
  • 機會矩陣
  • 業者情勢
  • 主要的投資考察

第5章 市場:各治療適應症

  • 肺癌症
  • 乳癌
  • 前列腺癌
  • 大腸癌
  • 惡性黑色素瘤
  • 其他種類的癌症
  • 腫瘤以外的適應

第6章 市場:各臨床應用

  • 治療監測
  • 預後、復發監測
  • 治療選擇
  • 診斷、篩檢

第7章 市場:生物標記的各類型

  • 核酸
  • 蛋白質
  • 細胞外小胞
  • 細胞

第8章 市場:各分析平台

  • NGS
  • 微陣列
  • PCR
  • 蛋白質體學
  • 其他

第9章 市場:各分析目的

  • 早期發現/篩檢
  • 治療指導
  • 監測
  • 診斷

第10章 市場:各循環生物標記

  • 循環腫瘤DNA(ctDNA)
  • 循環腫瘤細胞(CTC)
  • Cell-free DNA(cfDNA)
  • 其他

第11章 市場:各終端用戶

  • 醫生的研究室
  • 醫院
  • 臨床診斷檢驗室

第12章 各地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 比利時
    • 波蘭
    • 其他的歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲、紐西蘭
    • 泰國
    • 印尼
    • 越南
    • 其他的亞太地區
  • 其他全球地區
    • 南美
    • 中東、非洲

第13章 企業簡介

  • BECTON DICKINSON AND COMPANY (BD)
  • F HOFFMANN-LA ROCHE
  • BIO-RAD LABORATORIES INC
  • B BRAUN MELSUNGEN AG
  • BOSTON SCIENTIFIC CORPORATION
  • QIAGEN NV
  • PLANMECA OY
  • COOK MEDICAL INC
  • AD-TECH MEDICAL INSTRUMENT CORP
  • AGILENT TECHNOLOGIES INC
  • ARGON MEDICAL DEVICES INC
  • CINTEC MEDICAL LTD
  • FISCHER MEDICAL TECHNOLOGIES LLC
  • IMS INTERNAZIONALE MEDICO SCIENTIFICA SRL
目錄
Product Code: 16840

KEY FINDINGS

The global liquid bioscopy market is predicted to register a CAGR of 20.50% during the forecast period of 2020 to 2028. The primary factors propelling the market growth are growth in precision medicine, rising government initiatives, the growing pervasiveness of cancer in the older population, increasing potential of liquid biopsies, and technological advancements.

MARKET INSIGHTS

Due to rapid changes in consumer demands, diagnostic testing has been shifted from hospitals and commercial laboratories, to locations closer to the patient's home. This has resulted in minimizing the overall cost of testing. Most healthcare services in urban areas are delivered at home with a reduced focus on rural areas. Moreover, developing countries also have a high percentage of people residing in rural areas, with very few diagnostic centers and low accessibility. Thus, fatalities due to cancer are very high in rural environments. The increasing death toll can be attributed to a lack of awareness of the disease, leading to ignorance of diagnosis and treatment. Hence, it is anticipated that improved diagnostic tools, faster response times, easy availability of biopsy solutions at an inexpensive rate, and high amounts of research grants would lead to establishing numerous diagnostic centers, especially in rural areas and developing countries in the region. Consequently, the growing number of diagnostic centers are projected to offer a lucrative opportunity for biopsy solution providers and augment market growth.

REGIONAL INSIGHTS

Countries across the Asia Pacific, North America, Europe, and the rest of the world are analyzed to assess global liquid biopsy market growth. According to Inkwood Research, North America is estimated to garner the largest revenue share by the end of the forecast period. As a result of the increasing number of cancer cases, the demand for liquid biopsy in North America is projected to rise. Canada and the United States have superior biopsy technologies that specialize in detecting diseases at the early stages, thus reducing the countries' mortality rates.

COMPETITIVE INSIGHTS

As the global liquid biopsy market continues to emerge, regular and rapid developments are being witnessed. There are very few obstructions to innovations entering the market, resulting in medium to high levels of industry rivalry. Some of the established companies in the market include Cook Medical Inc, F Hoffmann-La Roche, Qiagen NV, Planmeca OY, Boston Scientific Corporation, Bio-Rad Laboratories, etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. RISING GOVERNMENT INITIATIVES
    • 3.2.2. GROWING PERVASIVENESS OF CANCER CASES IN OLDER POPULACE
    • 3.2.3. GROWING NUMBER OF DIAGNOSTIC CENTERS
    • 3.2.4. GROWTH OF PRECISION MEDICINE
    • 3.2.5. EMERGENCE OF TISSUE/TUMOR-AGNOSTIC DRUGS
    • 3.2.6. RISING POTENTIAL OF THE LIQUID BIOPSY
    • 3.2.7. TECHNOLOGICAL ADVANCEMENT
  • 3.3. KEY RESTRAINTS
    • 3.3.1. LACK OF CONSENSUS ON STANDARD OPERATING PROCEDURES (SOPS)
    • 3.3.2. POOR COMPENSATION STRUCTURES
    • 3.3.3. HIGH COST OF THE TEST
    • 3.3.4. LACK OF REIMBURSEMENT
    • 3.3.5. LACK OF SKILLED PROFESSIONALS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. KEY LIQUID BIOPSY INITIATIVES
  • 4.3. REGULATORY FRAMEWORK
  • 4.4. OPPORTUNITY MATRIX
  • 4.5. VENDOR LANDSCAPE
  • 4.6. KEY INVESTMENT INSIGHTS

5. MARKET BY THERAPEUTIC APPLICATION

  • 5.1. LUNG CANCER
  • 5.2. BREAST CANCER
  • 5.3. PROSTATE CANCER
  • 5.4. COLORECTAL CANCER
  • 5.5. MELANOMA CANCER
  • 5.6. OTHER TYPES OF CANCER
  • 5.7. NON-ONCOLOGY APPLICATION

6. MARKET BY CLINICAL APPLICATION

  • 6.1. TREATMENT MONITORING
  • 6.2. PROGNOSIS AND REOCCURRENCE MONITORING
  • 6.3. TREATMENT SELECTION
  • 6.4. DIAGNOSIS AND SCREENING

7. MARKET BY BIOMARKER TYPE

  • 7.1. NUCLEIC ACID
  • 7.2. PROTEIN
  • 7.3. EXTRACELLULAR VESICLES
  • 7.4. CELLS

8. MARKET BY ANALYSIS PLATFORM

  • 8.1. NGS
  • 8.2. MICROARRAY
  • 8.3. PCR
  • 8.4. PROTEOMICS
  • 8.5. OTHER ANALYSIS PLATFORMS

9. MARKET BY ANALYSIS PURPOSE

  • 9.1. EARLY DETECTION/SCREENING
  • 9.2. THERAPY GUIDANCE
  • 9.3. MONITORING
  • 9.4. DIAGNOSIS

10. MARKET BY PRODUCT

  • 10.1. CIRCULATING TUMOR DNA (CTDNA)
  • 10.2. CIRCULATING TUMOR CELLS (CTCS)
  • 10.3. CELL-FREE DNA (CFDNA)
  • 10.4. EXTRACELLULAR VESICLES AND OTHERS

11. MARKET BY END-USER

  • 11.1. PHYSICIANS' OFFICE LABORATORIES
  • 11.2. HOSPITALS
  • 11.3. CLINICAL DIAGNOSTIC LABORATORIES

12. GEOGRAPHICAL ANALYSIS

  • 12.1. NORTH AMERICA
    • 12.1.1. THE UNITED STATES
    • 12.1.2. CANADA
  • 12.2. EUROPE
    • 12.2.1. THE UNITED KINGDOM
    • 12.2.2. FRANCE
    • 12.2.3. GERMANY
    • 12.2.4. ITALY
    • 12.2.5. RUSSIA
    • 12.2.6. BELGIUM
    • 12.2.7. POLAND
    • 12.2.8. REST OF EUROPE
  • 12.3. ASIA PACIFIC
    • 12.3.1. JAPAN
    • 12.3.2. CHINA
    • 12.3.3. INDIA
    • 12.3.4. SOUTH KOREA
    • 12.3.5. AUSTRALIA & NEW ZEALAND
    • 12.3.6. THAILAND
    • 12.3.7. INDONESIA
    • 12.3.8. VIETNAM
    • 12.3.9. REST OF ASIA PACIFIC
  • 12.4. REST OF WORLD
    • 12.4.1. LATIN AMERICA
    • 12.4.2. MIDDLE EAST & AFRICA

13. COMPANY PROFILES

  • 13.1. BECTON DICKINSON AND COMPANY (BD)
  • 13.2. F HOFFMANN-LA ROCHE
  • 13.3. BIO-RAD LABORATORIES INC
  • 13.4. B BRAUN MELSUNGEN AG
  • 13.5. BOSTON SCIENTIFIC CORPORATION
  • 13.6. QIAGEN NV
  • 13.7. PLANMECA OY
  • 13.8. COOK MEDICAL INC
  • 13.9. AD-TECH MEDICAL INSTRUMENT CORP
  • 13.10. AGILENT TECHNOLOGIES INC
  • 13.11. ARGON MEDICAL DEVICES INC
  • 13.12. CINTEC MEDICAL LTD
  • 13.13. FISCHER MEDICAL TECHNOLOGIES LLC
  • 13.14. IMS INTERNAZIONALE MEDICO SCIENTIFICA SRL

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - LIQUID BIOPSY
  • TABLE 2: GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
  • TABLE 3: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 4: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 6: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 11: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES
  • TABLE 12: ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
  • TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 16: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 18: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: GLOBAL LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 21: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 22: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 23: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 24: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 25: ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 26: ASIA PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 27: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 28: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: KEY INVESTMENT INSIGHTS
  • FIGURE 5: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, IN 2019
  • FIGURE 6: GLOBAL LIQUID BIOPSY MARKET, BY LUNG CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL LIQUID BIOPSY MARKET, BY BREAST CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL LIQUID BIOPSY MARKET, BY PROSTATE CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL LIQUID BIOPSY MARKET, BY COLORECTAL CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL LIQUID BIOPSY MARKET, BY MELANOMA CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 11: GLOBAL LIQUID BIOPSY MARKET, BY OTHER TYPES OF CANCER, 2020-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL LIQUID BIOPSY MARKET, BY NON-ONCOLOGY APPLICATION, 2020-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, IN 2019
  • FIGURE 14: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL LIQUID BIOPSY MARKET, BY PROGNOSIS AND REOCCURRENCE MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL LIQUID BIOPSY MARKET, BY TREATMENT SELECTION, 2020-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS AND SCREENING, 2020-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, IN 2019
  • FIGURE 19: GLOBAL LIQUID BIOPSY MARKET, BY NUCLEIC ACID, 2020-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL LIQUID BIOPSY MARKET, BY PROTEIN, 2020-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES, 2020-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL LIQUID BIOPSY MARKET, BY CELLS, 2020-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, IN 2019
  • FIGURE 24: GLOBAL LIQUID BIOPSY MARKET, BY NGS, 2020-2028 (IN $ MILLION)
  • FIGURE 25: GLOBAL LIQUID BIOPSY MARKET, BY MICROARRAY, 2020-2028 (IN $ MILLION)
  • FIGURE 26: GLOBAL LIQUID BIOPSY MARKET, BY PCR, 2020-2028 (IN $ MILLION)
  • FIGURE 27: GLOBAL LIQUID BIOPSY MARKET, BY PROTEOMICS, 2020-2028 (IN $ MILLION)
  • FIGURE 28: GLOBAL LIQUID BIOPSY MARKET, BY OTHER ANALYSIS PLATFORMS, 2020-2028 (IN $ MILLION)
  • FIGURE 29: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, IN 2019
  • FIGURE 30: GLOBAL LIQUID BIOPSY MARKET, BY EARLY DETECTION/SCREENING, 2020-2028 (IN $ MILLION)
  • FIGURE 31: GLOBAL LIQUID BIOPSY MARKET, BY THERAPY GUIDANCE, 2020-2028 (IN $ MILLION)
  • FIGURE 32: GLOBAL LIQUID BIOPSY MARKET, BY MONITORING, 2020-2028 (IN $ MILLION)
  • FIGURE 33: GLOBAL LIQUID BIOPSY MARKET, BY DIAGNOSIS, 2020-2028 (IN $ MILLION)
  • FIGURE 34: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, IN 2019
  • FIGURE 35: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR DNA (CTDNA), 2020-2028 (IN $ MILLION)
  • FIGURE 36: GLOBAL LIQUID BIOPSY MARKET, BY CIRCULATING TUMOR CELLS (CTCS), 2020-2028 (IN $ MILLION)
  • FIGURE 37: GLOBAL LIQUID BIOPSY MARKET, BY CELL-FREE DNA (CFDNA), 2020-2028 (IN $ MILLION)
  • FIGURE 38: GLOBAL LIQUID BIOPSY MARKET, BY EXTRACELLULAR VESICLES AND OTHERS, 2020-2028 (IN $ MILLION)
  • FIGURE 39: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, IN 2019
  • FIGURE 40: GLOBAL LIQUID BIOPSY MARKET, BY PHYSICIANS' OFFICE LABORATORIES, 2020-2028 (IN $ MILLION)
  • FIGURE 41: GLOBAL LIQUID BIOPSY MARKET, BY HOSPITALS, 2020-2028 (IN $ MILLION)
  • FIGURE 42: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL DIAGNOSTIC LABORATORIES, 2020-2028 (IN $ MILLION)
  • FIGURE 43: NORTH AMERICA LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 44: THE UNITED STATES LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 45: CANADA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 46: EUROPE LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 47: THE UNITED KINGDOM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 48: FRANCE LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 49: GERMANY LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 50: ITALY LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 51: RUSSIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 52: BELGIUM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 53: POLAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 54: REST OF EUROPE LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 55: ASIA PACIFIC LIQUID BIOPSY MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 56: JAPAN LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 57: CHINA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 58: INDIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 59: SOUTH KOREA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 60: AUSTRALIA & NEW ZEALAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 61: THAILAND LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 62: INDONESIA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 63: VIETNAM LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 64: REST OF ASIA PACIFIC LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 65: REST OF WORLD LIQUID BIOPSY MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 66: LATIN AMERICA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 67: MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET, 2020-2028 (IN $ MILLION)